NCT02213107 2024-11-13
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Phase 2 Completed
Clinical Trials
9 trialsNCT00668642 2023-08-22
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Endeavor Health
Phase 2 Completed
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00403000 2013-05-01
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Roswell Park Cancer Institute
Phase 2 Completed
NCT00558363 2012-03-21
ARTS
GlaxoSmithKline
Phase 2 Completed